Aclidinium bromide/formoterol fumarate vs Umeclidinium
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Chronic Obstructive Pulmonary Disease pipeline
Aclidinium bromide/formoterol fumarate · Duaklir Pressair
Rights held by Azurity Pharmaceuticals and partners; US product discontinued
NCT01437397 · Phase 3 · completed
This was a large randomized, quadruple-blind, placebo- and active-controlled trial with 1,692 randomized participants, using the regulator-accepted clinical lung-function measure FEV1 as its primary endpoint. Results were mixed: the 400/12 μg combination significantly improved post-dose FEV1 versus aclidinium and trough FEV1 versus formoterol, whereas the 400/6 μg combination did not significantly improve trough FEV1 versus formoterol (p=0.133).
Reported efficacy
Change From Baseline in 1-hour Morning Post Forced Expiratory Volume in 1 Second (FEV1) (Week 24, 1-hour morning post-dose); Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide/Formoterol Fumarate (Week 24, morning pre-dose (trough)); Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide (Week 24, morning pre-dose (trough)): Change From Baseline in 1-hour Morning Post Forced Expiratory Volume in 1 Second (FEV1) (Week 24, 1-hour morning post-dose): AB/FF 400/12 μg 0.248 Litres (Standard Error 0.013) vs AB 400 μg 0.156 Litres (Standard Error 0.013) | FF 12 μg 0.138 Litres (Standard Error 0.013) | Placebo -0.05 Litres (Standard Error 0.013) (met)
Result source: NCT03022097
Umeclidinium · Incruse Ellipta
Marketed by GlaxoSmithKline
NCT02184611 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial in 308 patients using lung function (trough FEV1) as its primary measure, and umeclidinium produced a significantly greater improvement than placebo (least-squares mean difference 0.154 L, 95% CI 0.113 to 0.194, p<0.001).
Reported efficacy
Change From Baseline in Trough (Pre-bronchodilator) Forced Expiratory Volume in 1 Second (FEV1) on Treatment Day 169 (Baseline (Day 1) and Day 169): Change from baseline in trough FEV1 at Day 169 (primary endpoint): UMEC 62.5 mcg vs placebo, LS mean treatment difference 154 mL (95% CI 113, 194; p<0.001) (met)
Result source: NCT02184611
Results for Chronic Obstructive Pulmonary Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Aclidinium bromide/formoterol fumarate | Umeclidinium |
|---|---|---|
| Moderate or severe exacerbations, annualised rate | —Not reported | —Trial running · NCT06474039 |
| Trough FEV1, change | 0.1 vs -0.0+0.1 vs placeboNCT014373975 other results
| 0.1 vs -0.0+0.2 vs placeboNCT0218461121 other results
|
| SGRQ total, change | -6.6 vs -2.2−4.4 vs placeboNCT014373974 other results
| -6.2 vs -2.1−4 vs placeboNCT021526055 other results
|
| TDI focal score | 2.0 vs 0.6+1.4 vs placeboNCT014373975 other results
| 2.5 vs 1.6+0.9 vs placeboNCT02184611 |
Moderate or severe exacerbations, annualised rate
- Aclidinium bromide/formoterol fumarate
- —Not reported
- Umeclidinium
- —Trial running · NCT06474039
Trough FEV1, change
- Aclidinium bromide/formoterol fumarate
- 0.1 vs -0.0+0.1 vs placeboNCT01437397
5 other results
- 0.1 vs -0.0 NCT01437397
- 0.1 vs -0.1 NCT01462942
- 0.1 vs -0.1 NCT01462942
- 0.1 vs -0.1 NCT03022097
- 0.1 vs -0.1 NCT03022097
- Umeclidinium
- 0.1 vs -0.0+0.2 vs placeboNCT02184611
21 other results
- 0.1 vs -0.0 NCT01957163
- 0.1 vs -0.0 NCT01772147
- 0.1 vs -0.0 NCT01957163
- 0.1 vs -0.0 NCT01772134
- 0.1 vs -0.0 NCT01772147
- 0.1 vs -0.0 NCT01772134
- 0.1 vs -0.0 NCT02119286
- 0.1 vs -0.0 NCT02119286
- 0.2 vs 0.1 NCT02207829
- 0.2 vs 0.2 NCT02257385
- 0.1 vs 0.1 NCT02729051
- 0.2 vs 0.0 NCT02152605
- 0.2 vs 0.1 NCT01879410
- 0.1 vs -0.0 NCT02257372
- 0.1 vs -0.0 NCT03034915
- 0.1 vs 0.1 NCT02236611
- 0.1 vs 0.1 NCT02164539
- 0.2 vs 0.1 NCT02164539
- 0.1 vs 0.1 NCT02164539
- 0.2 vs 0.1 NCT02164539
- 0.2 vs -0.0 NCT02275052
SGRQ total, change
- Aclidinium bromide/formoterol fumarate
- -6.6 vs -2.2−4.4 vs placeboNCT01437397
4 other results
- -5.9 vs -2.2 NCT01437397
- -7.2 vs -6.5 NCT01462942
- -8.3 vs -6.5 NCT01462942
- -8.7 vs -4.7 NCT03022097
- Umeclidinium
- -6.2 vs -2.1−4 vs placeboNCT02152605
5 other results
- -7.3 vs -4.3 NCT02184611
- -7.0 vs -2.5 NCT02184611
- -5.8 vs -1.4 NCT02184611
- -5.8 vs -4.9 NCT02729051
- -5.0 vs -3.3 NCT03034915
TDI focal score
- Aclidinium bromide/formoterol fumarate
- 2.0 vs 0.6+1.4 vs placeboNCT01437397
5 other results
- 2.0 vs 0.6 NCT01437397
- 2.5 vs 1.2 NCT01462942
- 2.4 vs 1.2 NCT01462942
- 2.9 vs 2.1 NCT03022097
- 1.9 vs 1.9 NCT01908140
- Umeclidinium
- 2.5 vs 1.6+0.9 vs placeboNCT02184611
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Aclidinium bromide/formoterol fumarate: 4 of 4 rows · Umeclidinium: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Aclidinium bromide/formoterol fumarate | Umeclidinium |
|---|---|---|
| Dropout rate | 19.5%400/12 μga NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 7 more results18.3%400/6 μg NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 7.9%400/12 μg NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3 14.1% NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 8.8%400/12 μg NCT01462942 · Phase 3 10.5%400/6 μg NCT01462942 · Phase 3 32.4%400 μg/12 μg NCT01437540 · Phase 3 · registry result, not featured evidence 5%400/12 BID NCT03276078 · Phase 2 · registry result, not featured evidence | 13.7%62.5 mcgb NCT02184611 · Phase 3 show 25 more results8.9%125 µg QD NCT01772147 · Phase 3 · combination 12.3%62.5 µg QD NCT01772147 · Phase 3 · combination 5.3%62.5 µg NCT01957163 · Phase 3 · combination 8.7%125 µg NCT01957163 · Phase 3 · combination 3.4%125 µg NCT02119286 · Phase 3 · combination 5.3%62.5 µg NCT02119286 · Phase 3 · combination 10.7%125 µg QD NCT01772134 · Phase 3 · combination 6.9%62.5 µg QD NCT01772134 · Phase 3 · combination 11.7%62.5/25 mcg NCT03034915 · Phase 4 · registry result, not featured evidence —62.5/25 mcg NCT02275052 · Phase 4 · registry result, not featured evidence 5%62.5 mcg QD NCT02236611 · Phase 4 · registry result, not featured evidence 8.4%62.5 mcg+ICS/LABA NCT02257372 · Phase 4 · registry result, not featured evidence · combination 5.7%100/62.5/25 NCT02729051 · Phase 3 · registry result, not featured evidence 8.3%62.5 mcg QD NCT02207829 · Phase 3 · registry result, not featured evidence 4.6%62.5/25 µg NCT02257385 · Phase 3 · registry result, not featured evidence 7.3%62.5/25 mcg NCT02152605 · Phase 3 · registry result, not featured evidence —62.5/25mcg NCT02152605 · Phase 3 · registry result, not featured evidence —62.5/25 mcg NCT01879410 · Phase 3 · registry result, not featured evidence —62.5/25 µg NCT02014480 · Phase 3 · registry result, not featured evidence —62.5/25 µg once daily NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 3.5%100/250 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 4.3%100/125 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/15.6 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 2.5%100/62.5 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/250/25 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 6.2%400/12 μga NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 7 more results6.5%400/6 μg NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 1.1%400/12 μg NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3 4.7% NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 3.1%400/12 μg NCT01462942 · Phase 3 2.6%400/6 μg NCT01462942 · Phase 3 6.6%400 μg/12 μg NCT01437540 · Phase 3 · registry result, not featured evidence 5%400/12 BID NCT03276078 · Phase 2 · registry result, not featured evidence | 2.4%62.5 mcgb NCT02184611 · Phase 3 show 25 more results3%125 µg QD NCT01772147 · Phase 3 · combination 4.9%62.5 µg QD NCT01772147 · Phase 3 · combination 1%62.5 µg NCT01957163 · Phase 3 · combination 1.9%125 µg NCT01957163 · Phase 3 · combination 1%125 µg NCT02119286 · Phase 3 · combination 3.4%62.5 µg NCT02119286 · Phase 3 · combination 4.9%125 µg QD NCT01772134 · Phase 3 · combination 2.5%62.5 µg QD NCT01772134 · Phase 3 · combination 3.6%62.5/25 mcg NCT03034915 · Phase 4 · registry result, not featured evidence —62.5/25 mcg NCT02275052 · Phase 4 · registry result, not featured evidence 1.9%62.5 mcg QD NCT02236611 · Phase 4 · registry result, not featured evidence 5.9%62.5 mcg+ICS/LABA NCT02257372 · Phase 4 · registry result, not featured evidence · combination 4%100/62.5/25 NCT02729051 · Phase 3 · registry result, not featured evidence 2%62.5 mcg QD NCT02207829 · Phase 3 · registry result, not featured evidence 2.5%62.5/25 µg NCT02257385 · Phase 3 · registry result, not featured evidence 3.2%62.5/25 mcg NCT02152605 · Phase 3 · registry result, not featured evidence —62.5/25mcg NCT02152605 · Phase 3 · registry result, not featured evidence —62.5/25 mcg NCT01879410 · Phase 3 · registry result, not featured evidence —62.5/25 µg NCT02014480 · Phase 3 · registry result, not featured evidence —62.5/25 µg once daily NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 —100/250 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/125 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/15.6 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/62.5 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/250/25 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 5.7%400/12 μga NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 7 more results5.4%400/6 μg NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 7.2%400/12 μg NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3 7.5% NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 6%400/12 μg NCT01462942 · Phase 3 4.7%400/6 μg NCT01462942 · Phase 3 9.7%400 μg/12 μg NCT01437540 · Phase 3 · registry result, not featured evidence 5%400/12 BID NCT03276078 · Phase 2 · registry result, not featured evidence | 8.3%62.5 mcgb NCT02184611 · Phase 3 show 25 more results3%125 µg QD NCT01772147 · Phase 3 · combination 3%62.5 µg QD NCT01772147 · Phase 3 · combination 1%62.5 µg NCT01957163 · Phase 3 · combination 3.4%125 µg NCT01957163 · Phase 3 · combination 1.4%125 µg NCT02119286 · Phase 3 · combination 3.9%62.5 µg NCT02119286 · Phase 3 · combination 2.9%125 µg QD NCT01772134 · Phase 3 · combination 2%62.5 µg QD NCT01772134 · Phase 3 · combination 6%62.5/25 mcg NCT03034915 · Phase 4 · registry result, not featured evidence 3%62.5/25 mcg NCT02275052 · Phase 4 · registry result, not featured evidence 3.3%62.5 mcg QD NCT02236611 · Phase 4 · registry result, not featured evidence 5%62.5 mcg+ICS/LABA NCT02257372 · Phase 4 · registry result, not featured evidence · combination 10.4%100/62.5/25 NCT02729051 · Phase 3 · registry result, not featured evidence 3.3%62.5 mcg QD NCT02207829 · Phase 3 · registry result, not featured evidence 4.4%62.5/25 µg NCT02257385 · Phase 3 · registry result, not featured evidence —62.5/25 mcg NCT02152605 · Phase 3 · registry result, not featured evidence 6.9%62.5/25mcg NCT02152605 · Phase 3 · registry result, not featured evidence 3.2%62.5/25 mcg NCT01879410 · Phase 3 · registry result, not featured evidence 0.5%62.5/25 µg NCT02014480 · Phase 3 · registry result, not featured evidence 1.7%62.5/25 µg once daily NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 0.5%100/250 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/125 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/15.6 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/62.5 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/250/25 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | 400/12 μga chronic obstructive pulmonary disease 15.2% (placebo 17.5%) cough 5.1% (placebo 3.6%) nasopharyngitis 4.8% (placebo 3.6%) NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 7 more results400/6 μg chronic obstructive pulmonary disease 14.7% (placebo 17.5%) nasopharyngitis 5.1% (placebo 3.6%) cough 3.9% (placebo 3.6%) NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 400/12 μg upper respiratory tract infection 11.8% (placebo 8.9%) chronic obstructive pulmonary disease 9.5% (placebo 13%) NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3 chronic obstructive pulmonary disease 15% headache 6% nasopharyngitis 5.6% NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 400/12 μg chronic obstructive pulmonary disease 8.6% (placebo 11.9%) nasopharyngitis 7.8% (placebo 7.2%) headache 7.5% (placebo 8.2%) NCT01462942 · Phase 3 400/6 μg chronic obstructive pulmonary disease 9.4% (placebo 11.9%) nasopharyngitis 7.9% (placebo 7.2%) headache 7.1% (placebo 8.2%) NCT01462942 · Phase 3 400 μg/12 μg chronic obstructive pulmonary disease 27% urinary tract infection 6.6% nasopharyngitis 6.4% NCT01437540 · Phase 3 · registry result, not featured evidence | 62.5 mcgb upper respiratory tract infection 12.2% (placebo 12.9%) nasopharyngitis 9.3% (placebo 10.9%) dizziness 2.9% (placebo 2%) NCT02184611 · Phase 3 show 23 more results125 µg QD nasopharyngitis 5% (placebo 4.5%) headache 3% (placebo 4.5%) NCT01772147 · Phase 3 · combination 62.5 µg QD headache 4.4% (placebo 4.5%) nasopharyngitis 3% (placebo 4.5%) NCT01772147 · Phase 3 · combination 62.5 µg headache 4.4% (placebo 2.9%) back pain 3.4% (placebo 1.5%) nasopharyngitis 3.4% (placebo 3.4%) NCT01957163 · Phase 3 · combination 125 µg nasopharyngitis 4.8% (placebo 3.4%) headache 4.3% (placebo 2.9%) cough 3.4% (placebo 0.5%) NCT01957163 · Phase 3 · combination 125 µg nasopharyngitis 9.2% (placebo 10.7%) headache 1.9% (placebo 2.4%) back pain 1% (placebo 1.9%) NCT02119286 · Phase 3 · combination 62.5 µg nasopharyngitis 5.3% (placebo 10.7%) back pain 3.9% (placebo 1.9%) headache 3.9% (placebo 2.4%) NCT02119286 · Phase 3 · combination 125 µg QD headache 6.3% (placebo 4.9%) cough 2.4% (placebo 1.5%) nasopharyngitis 2.4% (placebo 4.9%) NCT01772134 · Phase 3 · combination 62.5 µg QD headache 4.4% (placebo 4.9%) cough 3.4% (placebo 1.5%) nasopharyngitis 2.5% (placebo 4.9%) NCT01772134 · Phase 3 · combination 62.5 mcg QD headache 8.1% nasopharyngitis 8.1% NCT02236611 · Phase 4 · registry result, not featured evidence 62.5 mcg+ICS/LABA nasopharyngitis 13.4% (placebo 14.5%) headache 3.4% (placebo 6.8%) cough 2.5% (placebo 4.3%) NCT02257372 · Phase 4 · registry result, not featured evidence · combination 100/62.5/25 viral upper respiratory tract infection 10.6% headache 6.1% upper respiratory tract infection 3.4% NCT02729051 · Phase 3 · registry result, not featured evidence 62.5 mcg QD headache 5.9% nasopharyngitis 5.3% NCT02207829 · Phase 3 · registry result, not featured evidence 62.5/25 µg headache 7.5% nasopharyngitis 6.6% cough 3.3% NCT02257385 · Phase 3 · registry result, not featured evidence 62.5/25mcg headache 6.5% (placebo 6.5%) nasopharyngitis 5.2% (placebo 6.5%) NCT02152605 · Phase 3 · registry result, not featured evidence 62.5/25 mcg headache 6.9% nasopharyngitis 4% NCT01879410 · Phase 3 · registry result, not featured evidence 62.5/25 µg once daily nasopharyngitis 4% headache 3.5% NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 100/250 µg nasopharyngitis 1.9% toothache 0.5% dysphonia 0% NCT02164539 · Phase 2 · registry result, not featured evidence · combination 100/125 µg dysphonia 6.5% nasopharyngitis 4.3% toothache 0% NCT02164539 · Phase 2 · registry result, not featured evidence · combination 100/15.6 µg nasopharyngitis 7.1% toothache 7.1% dysphonia 0% NCT02164539 · Phase 2 · registry result, not featured evidence · combination 100/62.5 µg nasopharyngitis 5% dysphonia 2.5% toothache 2.5% NCT02164539 · Phase 2 · registry result, not featured evidence · combination 100/250/25 µg dysphonia 0% nasopharyngitis 0% toothache 0% NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for 4 of these studies.
- bPopulation comparability has not been reviewed for 25 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Aclidinium bromide/formoterol fumarate
show 4 more results
show 1 more result
Umeclidinium
show 10 more results
show 2 more results
show 1 more result
show 3 more results
show 1 more result
show 1 more result
show 4 more results
show 1 more result
+ 12 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aclidinium bromide/formoterol fumarate's landscape · Umeclidinium's landscape